H-Index & Metrics Top Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine H-index 202 Citations 152,425 1,012 World Ranking 53 National Ranking 39

Research.com Recognitions

Awards & Achievements

2012 - Warren Alpert Foundation Prize For the discovery, preclinical and clinical development of bortezomib to FDA approval and front line therapy for the treatment of patients with multiple myeloma.

2010 - Member of the National Academy of Medicine (NAM)

Member of the Association of American Physicians

Overview

What is he best known for?

The fields of study he is best known for:

  • Gene
  • Cancer
  • Internal medicine

His primary scientific interests are in Multiple myeloma, Cancer research, Bortezomib, Internal medicine and Bone marrow. His work deals with themes such as Pharmacology and Dexamethasone, which intersect with Multiple myeloma. Kenneth C. Anderson interconnects Cell culture, Apoptosis, Protein kinase B, Signal transduction and Cell growth in the investigation of issues within Cancer research.

His Bortezomib research focuses on subjects like Proteasome inhibitor, which are linked to Cancer cell. The Internal medicine study combines topics in areas such as Gastroenterology, Endocrinology, Surgery and Oncology. His study in Bone marrow is interdisciplinary in nature, drawing from both Molecular biology, Stromal cell, Immune system and Peripheral blood mononuclear cell.

His most cited work include:

  • A phase 2 study of bortezomib in relapsed, refractory myeloma. (2325 citations)
  • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma (2128 citations)
  • International uniform response criteria for multiple myeloma (2049 citations)

What are the main themes of his work throughout his whole career to date?

Kenneth C. Anderson mainly focuses on Multiple myeloma, Cancer research, Internal medicine, Bortezomib and Immunology. The concepts of his Multiple myeloma study are interwoven with issues in Bone marrow, Dexamethasone and Pharmacology. His studies deal with areas such as Monoclonal antibody, Angiogenesis, Cytokine and In vivo as well as Bone marrow.

Within one scientific family, Kenneth C. Anderson focuses on topics pertaining to Apoptosis under Cancer research, and may sometimes address concerns connected to Cytotoxicity. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Surgery and Oncology. His work deals with themes such as Proteasome inhibitor, Proteasome and Refractory, which intersect with Bortezomib.

He most often published in these fields:

  • Multiple myeloma (50.62%)
  • Cancer research (39.80%)
  • Internal medicine (28.16%)

What were the highlights of his more recent work (between 2015-2021)?

  • Multiple myeloma (50.62%)
  • Cancer research (39.80%)
  • Internal medicine (28.16%)

In recent papers he was focusing on the following fields of study:

His primary areas of investigation include Multiple myeloma, Cancer research, Internal medicine, Oncology and Bortezomib. The Multiple myeloma study combines topics in areas such as Bone marrow and Transplantation. His research integrates issues of Cell culture, Cell growth, Antigen and Immunotherapy in his study of Cancer research.

In most of his Internal medicine studies, his work intersects topics such as Gastroenterology. Kenneth C. Anderson has included themes like Clinical trial, Survival rate, Confidence interval, Meta-analysis and Minimal residual disease in his Oncology study. His research in Bortezomib intersects with topics in Proteasome inhibitor, Proteasome and Pharmacology.

Between 2015 and 2021, his most popular works were:

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (828 citations)
  • Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma (471 citations)
  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group (359 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • Internal medicine

Kenneth C. Anderson spends much of his time researching Multiple myeloma, Cancer research, Internal medicine, Lenalidomide and Oncology. Kenneth C. Anderson combines subjects such as Survival rate and Bone marrow with his study of Multiple myeloma. His Cancer research study focuses on Stromal cell in particular.

The Internal medicine study which covers Gastroenterology that intersects with Antibody-drug conjugate and Indatuximab ravtansine. His Lenalidomide study combines topics in areas such as Surgery, Transplantation, Progressive disease and Thalidomide. The various areas that Kenneth C. Anderson examines in his Oncology study include Meta-analysis and Proportional hazards model.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Top Publications

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Paul G. Richardson;Bart Barlogie;James Berenson;Seema Singhal.
The New England Journal of Medicine (2003)

3226 Citations

International uniform response criteria for multiple myeloma

B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
Leukemia (2006)

2975 Citations

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin.
The New England Journal of Medicine (2005)

2881 Citations

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)

2775 Citations

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

Jake E. Delmore;Ghayas C. Issa;Madeleine E. Lemieux;Peter B. Rahl.
Cell (2011)

2411 Citations

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos.
The New England Journal of Medicine (2008)

2229 Citations

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Teru Hideshima;Paul Richardson;Dharminder Chauhan;Vito J. Palombella.
Cancer Research (2001)

2229 Citations

LOFAR: The LOw-Frequency ARray

M. P. van Haarlem;M. W. Wise;A. W. Gunst;G. Heald.
arXiv: Instrumentation and Methods for Astrophysics (2013)

2204 Citations

LOFAR: The LOw-Frequency ARray

M. P. van Haarlem;M. W. Wise;M. W. Wise;A. W. Gunst;George Heald.
Astronomy and Astrophysics (2013)

1889 Citations

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

Teru Hideshima;Dharminder Chauhan;Dharminder Chauhan;Yoshihito Shima;Yoshihito Shima;Noopur Raje;Noopur Raje.
Blood (2000)

1351 Citations

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us

Top Scientists Citing Kenneth C. Anderson

Meletios A. Dimopoulos

Meletios A. Dimopoulos

National and Kapodistrian University of Athens

Publications: 391

Shaji Kumar

Shaji Kumar

Mayo Clinic

Publications: 390

Morie A. Gertz

Morie A. Gertz

Mayo Clinic

Publications: 303

S. Vincent Rajkumar

S. Vincent Rajkumar

Mayo Clinic

Publications: 284

Angela Dispenzieri

Angela Dispenzieri

Mayo Clinic

Publications: 280

Philippe Moreau

Philippe Moreau

University of Nantes

Publications: 264

Antonio Palumbo

Antonio Palumbo

University of Turin

Publications: 260

Gareth J. Morgan

Gareth J. Morgan

New York University

Publications: 256

Evangelos Terpos

Evangelos Terpos

National and Kapodistrian University of Athens

Publications: 253

Robert A. Kyle

Robert A. Kyle

Mayo Clinic

Publications: 235

Paul G. Richardson

Paul G. Richardson

Harvard University

Publications: 234

Hartmut Goldschmidt

Hartmut Goldschmidt

University Hospital Heidelberg

Publications: 220

Robert Z. Orlowski

Robert Z. Orlowski

The University of Texas MD Anderson Cancer Center

Publications: 210

Sagar Lonial

Sagar Lonial

Emory University

Publications: 210

Martha Q. Lacy

Martha Q. Lacy

Mayo Clinic

Publications: 210

Something went wrong. Please try again later.